Project neuroARTEMIS

Conditions

• Depression
• Human Immunodeficiency Virus (HIV)
• Stimulant Use

Eligibility Criteria

Sex

ALL

Age

18 Years - 59 Years

Healthy Volunteers

Not accepted

Interventions

• ARTEMIS — BEHAVIORAL
  The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
• Contingency management for Antiretroviral (ARV) adherence — BEHAVIORAL
  All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.

Study Details

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Key Dates

Start date

Apr 29, 2025

Status verified

Sep 2025

Primary completion

May 31, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

189 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: ARTEMIS
  Participants in this arm will receive the ARTEMIS intervention immediately following randomization.
• Other: Waitlist Control (WLC)
  Participants in the WLC arm will be offered the ARTEMIS intervention after the final (6-month) follow-up.

Primary Outcome Measure

Neural Functional Connectivity [ Time Frame: Month 3 ]

Central Contacts

• Christina S Meade, PhD
  336-716-0695
  [email protected]
• Sheri L Towe, PhD
  336-716-4331
  [email protected]

Locations (1)

Find similar trials in Winston-Salem, NC

Related Studies

• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  PHASE3 · Recruiting · AbbVie · Bentonville, Arkansas
• Examining the Effects of Estradiol on Neural and Molecular Response to Reward
  PHASE4 · Recruiting · University of North Carolina, Chapel Hill · Chapel Hill, North Carolina
• Wellness App for Sleep Disturbance in Hematological Cancer Patients
  Recruiting · The University of Texas Health Science Center at San Antonio · Phoenix, Arizona
• Collaborative Care for Anxiety and Depression in Epilepsy
  Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina